Loading…
Hong Kong company developing traditional-Chinese-medicine formulations for ADHD and autism spectrum disorder.
Hong Kong company developing traditional-Chinese-medicine formulations for ADHD and autism spectrum disorder.
Has no product to sell, so there is no product revenue; it is funded by cash raised from selling shares and spends on research and trials. Its treatments are traditional herbal formulas not yet approved by Western drug regulators, so value rests on future data rather than sales. A small share of the stock trades freely.
Moat: none. Pre-revenue, unproven TCM approach with no Western regulatory approval or peer-reviewed efficacy data.
Headquarters: Hong Kong · Founded: 2014 · Employees: 10
Size Regencell Bioscience (RGC) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.61B, the 1626th largest of 3,117 United States companies the cockpit tracks. Shares closed at $5.27 on 6 Nov 2026.
Performance Over six months the shares fell 82.0%, against -4.7% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 21 in its peer set.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$404,543 | -$404,543 | -$392,743 | -$745,588 | -$769,687 |
| EBITDA | -$11.3M | -$11.3M | -$3.38M | -$3.99M | -$5.50M |
| Net income | -$11.7M | -$11.7M | -$3.58M | -$4.30M | -$5.87M |
| Free cash flow | -$7.70M | -$7.70M | -$3.27M | -$4.01M | -$4.99M |
| Capital expenditure | $0 | $0 | $152,689 | $5,376 | $27,392 |
| Total debt | n/a | $295,811 | $544,415 | $85,741 | $463,669 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Regencell Bioscience RGC | $2.61B | -82% | n/a | n/a | n/a | n/a |
| Supernus Pharmaceuticals SUPN | $5.43B | -49% | +16% | 45% | 4.1× | 4.2% |
| Jazz Pharmaceuticals Public JAZZ | $15.1B | +4% | +13% | 25% | 3.8× | -3.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RGC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -30.9% | -1.3% | lowest of 21 |
| 6-month return | -82.0% | -4.7% | lowest of 21 |
| Distance from 52-week high | -92.4% | -25.2% | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Regencell Bioscience RGC | United States | $2.61B | -82% | n/a | n/a | n/a | n/a | n/a |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.58B | +9% | -9% | -6% | 2.4× | 49.9% | +19.3% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.68B | +14% | +50% | 26% | 10.9× | n/a | n/a |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.70B | -20% | -14% | 16% | 4.5× | 4.6% | +4.8% |
| Acrobiosystems 301080.SZ | China | $2.72B | +95% | +29% | 17% | 16.7× | 45.0% | +27.7% |
| Almirall ALM.MC | Spain | $2.74B | -2% | +24% | 8% | 2.1× | 7.3% | +6.5% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.48B | -6% | 0% | -73% | 17.5× | n/a | n/a |
| Kangmei Pharmaceutical 600518.SS | China | $2.77B | -22% | -6% | -7% | 3.5× | n/a | n/a |
| BioArctic BIOA-B.ST | Sweden | $2.78B | -3% | -46% | 22% | 25.3× | 25.7% | +100.1% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.80B | -43% | +153% | -7% | 16.6× | 42.1% | +22.9% |
| Vericel VCEL | United States | $2.80B | +63% | +23% | 6% | 8.9× | 50.7% | +17.3% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.86B | -4% | -12% | 18% | 1.6× | -13.1% | +2.4% |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.91B | -59% | +21% | 7% | 15.4× | n/a | n/a |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.32B | +18% | -7% | 15% | 1.8× | -9.1% | -1.5% |
| InnoCare Pharma 688428.SS | China | $2.31B | -2% | +135% | 35% | 3.3× | -8.8% | +344.2% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.31B | -7% | +4% | 10% | 1.5× | -2.2% | -5.8% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.29B | -14% | +18% | n/a | 4.4× | 1.6% | +0.3% |
| Betta Pharmaceuticals 300558.SZ | China | $3.01B | -9% | +16% | 11% | 5.8× | 25.2% | +14.0% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.26B | -35% | 0% | -47% | 34.7× | n/a | n/a |
| IDEAYA Biosciences IDYA | United States | $3.02B | +10% | -83% | -1,267% | 60.5× | n/a | n/a |
| NewAmsterdam Pharma NAMS | United States | $2.26B | -51% | -26% | -900% | 62.8× | n/a | n/a |